QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
NASDAQ:VALN

Valneva (VALN) Stock Forecast, Price & News

$12.61
-0.39 (-3.00%)
(As of 06/7/2023 ET)
Compare
Today's Range
$12.20
▼
$12.90
50-Day Range
$9.45
▼
$13.36
52-Week Range
$9.07
▼
$33.76
Volume
15,048 shs
Average Volume
7,571 shs
Market Capitalization
$875.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Valneva MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
74.5% Upside
$22.00 Price Target
Short Interest
Healthy
0.03% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.47) to ($0.43) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.77 out of 5 stars

Medical Sector

676th out of 981 stocks

Biological Products, Except Diagnostic Industry

110th out of 159 stocks

See Top Rated MarketRank™ Stocks Here

VALN stock logo

About Valneva (NASDAQ:VALN) Stock

Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.

Receive VALN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Valneva and its competitors with MarketBeat's FREE daily newsletter.

VALN Stock News Headlines

June 7, 2023 | finance.yahoo.com
VALNEVA - Declaration of shares and voting rights: May 31, 2023
May 31, 2023 | finance.yahoo.com
Valneva Announces the Availability of Documentation for its Shareholder Meeting
June 7, 2023 | Legacy Research (Affiliate) (Ad)
Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
May 31, 2023 | finance.yahoo.com
Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June
May 30, 2023 | finance.yahoo.com
Valneva Files for Chikungunya Vaccine Authorization with Health Canada
May 25, 2023 | msn.com
Lyme Vaccines Are Finally Coming, and They May Not Look Like You'd Expect
May 23, 2023 | msn.com
France stocks lower at close of trade; CAC 40 down 1.33%
May 18, 2023 | americanbankingnews.com
Valneva (NASDAQ:VALN) Stock Price Down 5.1%
June 7, 2023 | Legacy Research (Affiliate) (Ad)
Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
May 17, 2023 | americanbankingnews.com
Valneva (NASDAQ:VALN) Sees Strong Trading Volume
May 15, 2023 | americanbankingnews.com
Valneva SE (NASDAQ:VALN) Short Interest Update
May 13, 2023 | americanbankingnews.com
Valneva (NASDAQ:VALN) Shares Gap Up to $12.10
May 11, 2023 | marketwatch.com
2030, Oral Vaccines Market Research
May 7, 2023 | news.yahoo.com
Rebound in travel helps vaccine maker Valneva post smaller-than-expected loss
May 6, 2023 | americanbankingnews.com
Valneva (NASDAQ:VALN) Price Target Cut to $22.00 by Analysts at HC Wainwright
May 6, 2023 | americanbankingnews.com
Head-To-Head Review: Vigil Neuroscience (NASDAQ:VIGL) & Valneva (NASDAQ:VALN)
May 4, 2023 | finance.yahoo.com
VALNEVA - Declaration of shares and voting rights - April 30, 2023
May 4, 2023 | finance.yahoo.com
UPDATE 2-Rebound in travel helps vaccine maker Valneva post smaller-than-expected loss
May 4, 2023 | finance.yahoo.com
Valneva Reports First Quarter 2023 Financial Results and Provides Corporate Updates
April 26, 2023 | americanbankingnews.com
Valneva (NASDAQ:VALN) Stock Price Up 4.2%
April 19, 2023 | msn.com
Rutgers Is A Test Site For First-Ever Kids' Vaccine For Lyme Disease
April 15, 2023 | americanbankingnews.com
Valneva (NASDAQ:VALN) Shares Gap Down to $11.62
April 6, 2023 | americanbankingnews.com
Valneva (NASDAQ:VALN) Trading 5.7% Higher
April 6, 2023 | finance.yahoo.com
VALNEVA - Declaration of shares and voting rights - March 31, 2023
April 5, 2023 | americanbankingnews.com
Financial Contrast: Valneva (VALN) and Its Rivals
April 5, 2023 | marketwatch.com
Oral Vaccines Market 2023 Size and Forecast to 2031
April 1, 2023 | americanbankingnews.com
Valneva (NASDAQ:VALN) Shares Gap Up to $10.03
See More Headlines

VALN Price History

VALN Company Calendar

Last Earnings
3/23/2023
Today
6/07/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VALN
CUSIP
N/A
CIK
1836564
Web
valneva.com
Phone
33-2-28-07-37-10
Fax
N/A
Employees
762
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$22.00
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$22.00
Forecasted Upside/Downside
+70.5%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.46)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-150,960,000.00
Net Margins
-38.20%
Pretax Margin
-40.08%
Return on Equity
-81.79%
Return on Assets
-21.22%

Debt

Debt-to-Equity Ratio
0.41
Current Ratio
1.48
Quick Ratio
1.33

Sales & Book Value

Annual Sales
$380.73 million
Price / Sales
2.35
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.35 per share
Price / Book
3.85

Miscellaneous

Outstanding Shares
69,450,000
Free Float
59,093,000
Market Cap
$895.91 million
Optionable
Not Optionable
Beta
2.61

Key Executives

  • Mr. Thomas Lingelbach (Age 59)
    Chairman of the Management Board, Pres & CEO
    Comp: $820.44k
  • Mr. Franck Grimaud MBA (Age 55)
    Director Gen., Chief Bus. Officer & Member of Management Board
    Comp: $514.52k
  • Mr. Frederic Jacotot (Age 57)
    VP of Legal & IP, Gen. Counsel, Corp. Sec. and Member of Management Board
    Comp: $403.84k
  • Dr. Juan-Carlos Jaramillo M.D. (Age 51)
    Chief Medical Officer & Member of the Management Board
    Comp: $562.34k
  • Mr. Peter Buhler (Age 51)
    CFO & Management Board Member
  • Mr. Perry Celentano
    Interim Chief Operating Officer
  • Ms. Dipal Patel
    Chief Commercial Officer & Member of Management Board
  • Mr. Joshua Drumm Ph.D.
    VP of Investor Relations
  • Ms. Laetitia Bachelot-Fontaine
    VP of Global Communications & European Investor Relations
  • Mr. Gerald Strohmaier
    VP of Human Resource

Key Competitors

View All Competitors













VALN Stock - Frequently Asked Questions

Should I buy or sell Valneva stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Valneva in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" VALN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VALN, but not buy additional shares or sell existing shares.
View VALN analyst ratings or view top-rated stocks.

What is Valneva's stock price forecast for 2023?

3 Wall Street analysts have issued 1 year price targets for Valneva's shares. Their VALN share price forecasts range from $22.00 to $22.00. On average, they anticipate the company's stock price to reach $22.00 in the next year. This suggests a possible upside of 70.5% from the stock's current price.
View analysts price targets for VALN or view top-rated stocks among Wall Street analysts.

How have VALN shares performed in 2023?

Valneva's stock was trading at $12.72 at the beginning of the year. Since then, VALN shares have increased by 1.4% and is now trading at $12.90.
View the best growth stocks for 2023 here.

When is Valneva's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our VALN earnings forecast.

How were Valneva's earnings last quarter?

Valneva SE (NASDAQ:VALN) announced its quarterly earnings data on Thursday, March, 23rd. The company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of $0.29 by $0.94. The company had revenue of $113.75 million for the quarter, compared to analyst estimates of $110.50 million. Valneva had a negative net margin of 38.20% and a negative trailing twelve-month return on equity of 81.79%.

What guidance has Valneva issued on next quarter's earnings?

Valneva issued an update on its FY 2023 earnings guidance on Friday, May, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $236.11 million-$279.04 million, compared to the consensus revenue estimate of $384.53 million.

When did Valneva IPO?

(VALN) raised $99 million in an initial public offering on Thursday, May 6th 2021. The company issued 3,500,000 shares at $28.24 per share. Goldman Sachs, Jefferies, Guggenheim Securities and Bryan, Garnier & Co. served as the underwriters for the IPO.

What is Valneva's stock symbol?

Valneva trades on the NASDAQ under the ticker symbol "VALN."

How do I buy shares of Valneva?

Shares of VALN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Valneva's stock price today?

One share of VALN stock can currently be purchased for approximately $12.90.

How much money does Valneva make?

Valneva (NASDAQ:VALN) has a market capitalization of $895.91 million and generates $380.73 million in revenue each year. The company earns $-150,960,000.00 in net income (profit) each year or ($2.46) on an earnings per share basis.

How many employees does Valneva have?

The company employs 762 workers across the globe.

How can I contact Valneva?

The official website for the company is valneva.com. The company can be reached via phone at 33-2-28-07-37-10 or via email at investors@valneva.com.

This page (NASDAQ:VALN) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -